SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to mixed reactions following its earnings release and subsequent stock movement, with community members debating whether the stock is overvalued. A significant point of discussion is Michael Burry's reported short position against the company. Despite positive earnings news, the stock's high valuation and potential AI bubble concerns are driving bearish sentiment.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI CRYPTO is gaining attention, particularly within communities focused on the Solana ecosystem, with some users expressing bullish sentiment while others discuss challenges. The community emphasizes a shared vision and encourages building together, fostering a sense of unity despite market conditions.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid discussions about a confirmatory trial and its potential impact on existing PMO therapies, which are facing scrutiny, while Elevidys sales remain a key focus. The community is weighing the implications for future revenue and potential FDA actions, with some speculating about a possible Roche buyout amid the uncertainty. Discussions also involve management's handling of recent data releases and their overall strategy.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as investors assess the implications of Q3 earnings, which included a massive EPS beat, even as some profit forecasts fell slightly short. The community is actively discussing the company's growth in bookings and trips, particularly the impact of Uber One memberships, while also debating whether the stock is currently undervalued given its market dominance and future potential in autonomous vehicles. Short-term manipulation and broader market conditions are also being considered as factors influencing the stock's price movement.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is trending amidst mixed sentiment, with some traders citing potential partnerships and real-world utility while others express concerns about its price action and long-term viability. Community discussions revolve around identifying key resistance levels and whether the current market cap is justified. Speculation about future developments and potential catalysts continues to fuel the conversation.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending amid discussions about its potential as a leading privacy coin and a hedge against Bitcoin's volatility, as some community members suggest it could reach new all-time highs. The conversations also highlight its upcoming anniversary, possibly leading to increased attention and speculation about future developments. Simultaneously, some traders are noting its overbought conditions and anticipating a potential pullback.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as community members assess the implications of recent earnings, raised guidance, and a notable dividend yield. Discussions include whether the market is undervaluing the stock, and speculation on potential acquisitions in the competitive obesity therapeutics market with some suggesting it may be a good long-term hold. Additionally, Michael Burry's position in PFE calls is generating buzz among investors.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin's recent price volatility has the community debating whether a longer-term correction is underway. Some traders believe institutions are strategically selling off, while others see the dip as a bear trap before a potential rally toward previous highs. Discussions also involve the influence of broader market factors, such as the Nasdaq and potential government actions, on Bitcoin's price.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending as investors discuss the company's recent earnings report, which revealed revenue growth and cash flow positivity. Community members are debating whether the current valuation is justified amidst competition and broader market conditions. Some are optimistic about the company's future prospects, citing potential AI modeling and strategic partnerships with established brands.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

SLAP is trending as the community rallies around the project, emphasizing its strong team and IRL partnerships. Talk centers on the meme-friendly nature of the token and the consistent grind of the team. Community members express excitement about the future and encourage others to join.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>William Blair downgraded Fiserv to ‘Market Perform’ from ‘Outperform’ and noted that it no longer recommends the stock, given a "shocking" third quarter.</li><li>Wolfe Research downgraded Fiserv to ‘Peer Perform’ from ‘Outperform,’ according to TheFly, on the heels of the guidance cut that it says "raised structural concerns."</li><li>Fiserv announced that Paul Todd has been named the company’s Chief Financial Officer, effective October 31, succeeding Robert Hau.</li></ul>Fiserv Inc. (FI) shares were down nearly 44%,&nbsp;on track for&nbsp;their largest one-day decline on Wednesday, as the company also witnessed multiple Wall Street downgrades following leadership transitions and a cut in annual forecasts.Wolfe Research downgraded Fiserv to ‘Peer Perform’ from ‘Outperform,’ according to TheFly on the heels of the guidance cut that it says "raised structural concerns." The firm noted that it was "tactically cautious" and previewed a potential guidance cut.The firm said that the combination of materially weaker third-quarter results across segments, along with acknowledgement of several short-term and unsustainable levers used at the company in recent years that need to be reversed, led Wolfe Research to see "too much uncertainty in the medium-term through a necessary transition period.”The company stock fell about 44%, hitting its biggest percentage drop ever at $71.22, according to Koyfin. Retail sentiment on Fiserv jumped to ‘extremely bullish’ from ‘bearish’ territory compared to a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<h2 class="st-heading-2">William Blair Calls It A “Shocking Q3”</h2>William Blair downgraded Fiserv to ‘Market Perform’ from ‘Outperform,’ according to TheFly. The firm noted that it no longer recommends the stock given a "shocking" third-quarter revenue and earnings per share miss and abrupt management transition.Relatively new CEO Mike Lyons is now in a difficult position to figure out what went wrong, the firm noted, adding that it has "low conviction" in the underpinnings of Fiserv's merchant competitive position.On Wednesday, the company announced that Paul Todd has been named the company’s Chief Financial Officer, effective October 31, succeeding Robert Hau, who will serve as a senior advisor through the first quarter of 2026.<h2 class="st-heading-2">Buying Opportunity In Fiserv Peers</h2>Wells Fargo said that it sees buying opportunities in Fiserv, Global Payments (GPN), Block (XYZ) and Toast (TOST) with the stocks trading down in sympathy with Fiserv.Fiserv's issues are largely company-specific and execution related, which is likely benefitting its peers, Wells Fargo said. As such, the firm said it believes read-throughs from the company's earnings report to peers are "misguided" and still expects FIS, Global Payments, Block and Toast to report solid results.<a href="https://stocktwits.com/symbol/FI">Shares of Fiserv</a> have declined over 65% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/caterpillar-sees-strong-growth-in-energy-segment-fueled-by-ai-infrastructure-demand/cLGZsDmR3wD">Caterpillar Sees Strong Growth In Energy Segment Fueled By AI Infrastructure Demand</a>

In this photo illustration, the Fiserv company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Fiserv Shares Plunge 44% In Record One-Day Drop As Company Gets Wall Street Downgrades On Leadership Changes, Forecast Cuts

Wolfe Research downgraded Fiserv to ‘Peer Perform’ from ‘Outperform,’ according to TheFly, on the heels of the guidance cut that it says "raised structural concerns."

Equity

<ul class="summary-bullets"><li>The study was designed to study the efficacy and safety of Encaleret and enrolled 70 adults with ADH1.</li><li>76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment.</li><li>The company now plans to submit a new drug application to the U.S. Food and Drug Administration in the first half of 2026. &nbsp;</li></ul>Shares of BridgeBio Pharma, Inc. (BBIO) rose 4% on Wednesday afternoon after the company announced that its late-stage study of Encaleret in patients with autosomal dominant hypocalcemia type 1 met all primary and key secondary endpoints.This marks the company’s second positive trial result announcement this week. The Encaleret<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.bridgebio.com/news/news-details/2025/BridgeBio-Reports-Positive-Phase-3-Topline-Results-for-Encaleret-in-Patients-with-Autosomal-Dominant-Hypocalcemia-Type-1/default.aspx"> study</a> was designed to study the efficacy and safety of the drug and enrolled 70 adults with ADH1– autosomal dominant hypocalcemia type 1 – a genetic disorder that causes low blood calcium levels, a condition known as hypocalcemia. Symptoms, which can range from none to severe, include muscle spasms, cramps, tingling sensations, and, in severe cases, seizures.<h2 class="st-heading-2">Trial Outcomes</h2>76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment compared to 4% when on conventional therapy, the company said. Furthermore, the drug was well-tolerated, the company noted.The company now plans to submit a new drug application to the U.S. Food and Drug Administration (FDA) in the first half of 2026, followed by an application to the European Medicines Agency.The company also intends to initiate registrational studies of Encaleret in chronic hypoparathyroidism and pediatric ADH1 in 2026. The trial in pediatric ADH1 is slated for the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BBIO">BBIO stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.A Stocktwits user termed the news great but expressed disappointment that the stock didn't rally further.<stembedurl>https://stocktwits.com/SugarSlim/message/634124724</stembedurl>Wednesday’s results come after the company <a href="https://stocktwits.com/news-articles/markets/equity/bbio-stock-soars-after-experimental-drug-shows-improvement-in-inherited-muscle-disorder-in-late-stage-trial/cLG04ksR3Mm">announced</a> on Monday that limb-girdle muscular dystrophy type 2I/R9 patients treated with BBP-418 in a late-stage study demonstrated improvements in motor and pulmonary function at 12 months.BBIO stock is up by 145% this year and by about 175% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/akebia-therapeutics-stock-slumps-after-fda-meeting-ends-without-path-forward-for-vafseo-label-expansion/cLGZtPhR3wx">Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results 

76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment.

The company also intends to initiate registrational studies of Encaleret in chronic hypoparathyroidism and pediatric ADH1 in 2026.

<ul class="summary-bullets"><li>Fiserv said that Todd previously served as the Chief Financial Officer of Global Payments and has been serving as a special advisor to the executive leadership team for the last several weeks.</li><li>CEO Mike Lyons said the company’s current performance is not where it wants it to be, nor where stakeholders expect it to be.</li><li>The company now expects 2025 adjusted earnings per share to come between $8.50 and $8.60, down from the previous forecast of $10.15 to $10.30.</li></ul>Shares of&nbsp;Fiserv Inc. (FI)&nbsp;tumbled by more than 42% in early trading after the company announced several leadership transitions and forecast annual organic revenue growth of 3.5% to 4%, down from its prior forecast of about 10%.Fiserv now expects 2025 adjusted earnings per share (EPS) to come between $8.50 and $8.60, down from the previous forecast of $10.15 to $10.30.On Wednesday, the company announced that Paul Todd has been named the company’s Chief Financial Officer, effective October 31, succeeding Robert Hau, who will serve as a senior advisor through the first quarter of 2026.Fiserv said that Todd previously served as the Chief Financial Officer of Global Payments and has been serving as a special advisor to the executive leadership team for the last several weeks.<h2 class="st-heading-2">Leadership Changes</h2>&nbsp;“After a thorough analysis of all aspects of the business, we have identified opportunities to prioritize and enhance client focus across key strategic pillars that build on Fiserv’s strengths and promote long-term value,” Fiserv CEO Mike Lyons said.“The appointments to our executive leadership team and Board will help catalyze these efforts to achieve our standards of excellence and enable a customer-centric culture,” he added.Fiserv said that Takis Georgakopoulos, its current Chief Operating Officer of Technology and Merchant Solutions, and Dhivya Suryadevara, most recently CEO of Optum Financial Services and Optum Insight at UnitedHealth Group, will serve as Co-Presidents, effective December 1, 2025.&nbsp;<h2 class="st-heading-2">Fiserv’s Q3 Results</h2>The company said its quarterly adjusted revenue increased 1% to $4.92 billion, below Wall Street expectations of $5.34 billion, according to data compiled by Fiscal AI.&nbsp; Fiserv’s third-quarter adjusted EPS came in at $2.04, missing estimates of $2.65.“Our current performance is not where we want it to be nor where our stakeholders expect it to be,” Lyons said.Retail sentiment on Fiserv jumped to ‘extremely bullish’ territory from ‘bearish’ territory compared to a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<a href="https://stocktwits.com/symbol/FI">Shares of Fiserv</a> have declined by over 65% this year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nesr-stock-rises-17-after-winning-multi-billion-dollar-saudi-aramco-contract/cLGZNy5R3w7">NESR Stock Rises 17% After Winning Multi-Billion-Dollar Saudi Aramco Contract</a>

In this photo illustration, the Fiserv logo is displayed on a smartphone screen, with the company's branding visible in the background, on April 20, 2025, in Chongqing, China. (Photo by Cheng Xin/Getty Images)

Fiserv Stock Plunges Over 40% As New CFO Paul Todd Steps In Amid Leadership Overhaul, Profit Warning

Fiserv now expects 2025 adjusted earnings per share to come between $8.50 and $8.60, down from the previous forecast of $10.15 to $10.30.

<ul class="summary-bullets"><li>CEO Barbara Weber said that across the 16 cancer types enrolled in the trial, the objective response rate was 27% in patients with a median follow-up of 9.4 months.&nbsp;</li><li>The company also announced the pricing of an underwritten offering of 21 million shares of its common stock and pre-funded warrants to purchase up to 3.2 million shares of its common stock. &nbsp;</li></ul>Tango Therapeutics, Inc. (TNGX) on Thursday announced $225 million in financing on the heels of positive data from its ongoing study of Vopimetostat in patients with MTAP-deleted cancers.CEO Barbara Weber <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/23/3171895/0/en/Tango-Therapeutics-Reports-Positive-Data-from-Ongoing-Phase-1-2-Study-with-Vopimetostat-TNG462-in-Patients-with-MTAP-deleted-Cancers.html">said</a> that across the 16 cancer types enrolled in the trial, the objective response rate (ORR) was 27% in patients with a median progression-free survival of 6.4 months.In 2L MTAP-deleted pancreatic cancer, the median progression-free survival (PFS) was 7.2 months, and the ORR was 25% in the study. The company now expects to initiate a pivotal trial in MTAP-deleted pancreatic cancer patients who have received one prior line of therapy in 2026, with about 300 patients. The company is slated to consult with the U.S. Food and Drug Administration on trial design later this quarter.Vopimetostat is being evaluated as a monotherapy and in combination clinical studies. According to Tango, methylthioadenosine phosphorylase (MTAP) deletions occur in 10-15% of all human cancers, including approximately 35% of pancreatic cancers and 15% of lung cancers. This loss creates a metabolic vulnerability because the MTAP enzyme normally breaks down methylthioadenosine (MTA), which is toxic when it builds up.<h2 class="st-heading-2">Financing Details</h2>The company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/23/3171915/0/en/Tango-Therapeutics-Announces-225-Million-Financing.html">announced</a> the pricing of an underwritten offering of 21 million shares of its common stock and pre-funded warrants to purchase up to 3.2 million shares of its common stock. The offering price of each share of common stock is $8.66, it stated. The gross proceeds from the offering is expected to be about $210 million, it added.The offering is expected to close on or about October 24, subject to customary conditions. Participants in the offering include a large, unnamed institutional investor, in addition to Farallon Capital Management, TCGX, Balyasny Asset Management, Woodline Partners LP, and others, the company said.Tango added that it has also entered into a securities purchase agreement for a private investment in public equity and is selling about 1.7 million shares of its common stock for $8.66 per share to raise gross proceeds of about $15 million.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/TNGX">TNGX shares</a> traded 8% higher in the pre-market session at the time of writing. On Stocktwits, retail sentiment around TNGX jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.TNGX stock is up by 180% this year and by about 38% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/harmony-biosciences-raises-full-year-revenue-guidance-ahead-of-earnings/cLG4ilnR3rG">Harmony Biosciences Raises Full-Year Revenue Guidance Ahead Of Earnings: Why Are Wakix Franchise Numbers Crucial?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tango Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Tango Therapeutics Stock Soars Pre-Market On $225M Financing, Positive Study Data For Cancer Therapy

CEO Barbara Weber said that across the 16 cancer types enrolled in the trial, the objective response rate (ORR) was 27% in patients with a median follow-up of 9.4 months. 

<ul><li>The company said that treatment-related adverse events were observed in the study for the first few doses but ceased with continuous dosing.</li><li>The Data Monitoring Committee found no convincing evidence that the serious adverse event is related to ARCT-032 and approved the study to proceed. &nbsp;</li></ul>Arcturus Therapeutics Holdings (ARCT) on Wednesday announced interim results from a mid-stage trial of its ARCT-032 therapy in people with cystic fibrosis.In a cohort of the study, six patients with cystic fibrosis received inhaled 10 mg doses of ARCT-032 daily over 28 days.<h2 class="st-heading-2">What’s Driving Down The Stock?</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-provides-interim-phase-2-data-cystic">reported</a> that treatment-related adverse events were observed in the study during the initial doses but ceased with continuous dosing.However, the Data Monitoring Committee found no convincing evidence that the serious adverse event is related to ARCT-032 and approved the study to proceed, the company said. One treatment-related adverse event also occurred in a participant after the end of the dosing period, it said. Furthermore, the treatment was generally safe and well-tolerated, the company added.However, shares of the company fell 58% on Wednesday. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARCT">ARCT stock</a> rose from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<h2 class="st-heading-2">What Are The Firm’s Plans Ahead?</h2>Arcturus noted on Wednesday that an expanded third cohort is ongoing. The company aims to enroll up to six subjects in the cohort if there is a dose escalation response at 15 mg and if ARCT-032 continues to be generally safe and well-tolerated.The company also said that it intends to kickstart a 12-week safety and preliminary efficacy study in up to 20 cystic fibrosis participants in the first half of 2026.Cystic fibrosis (CF) is an inherited genetic disorder that causes thick, sticky mucus to build up in the body's organs, primarily affecting the lungs and pancreas. It is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.<blockquote>“We are particularly encouraged by the early signals of mucus plug reduction in Class I CF participants treated with ARCT-032 because Class I CF individuals do not produce CFTR and therefore do not respond to available CFTR modulator therapy.”— Juergen Froehlich, Chief Medical Officer, Arcturus</blockquote>ARCT stock is down 43% this year and 51% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-to-recall-nearly-13000-vehicles-in-us/cLG57HOR3q4">Tesla To Recall Nearly 13,000 Vehicles In US, But Retail Has Its Eyes Set On Q3 Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Medical syringe is seen with Arcturus Therapeutics company logo displayed on a screen in the background in this illustration photo taken in Poland on June 16, 2020. (Photo Illustration by Jakub Porzycki/NurPhoto via Getty Images)

Arcturus Therapeutics Stock Plunges Over 58% Today: What’s Causing The Sell-Off?

The company said that treatment-related adverse events were observed in the study for the first few doses but ceased with continuous dosing.

Carvana (CVNA) stock was one of the top trending tickers on Stocktwits after the company’s shares fell nearly 6% in afternoon trading, with recent bankruptcies of subprime lender Tricolor and auto supplier First Brands Group putting the focus on auto-related firms.BTIG maintained a ‘Buy’ rating and $450 price target on Carvana, according to TheFly. The firm noted that the company's September Asset-Backed Securities performance data for its closely-watched 2025-N1 issuance has shown signs of improvement as the pace of cumulative net loss development slowed and 30- and 60-day delinquencies declined.The firm said that while it sees the September numbers as "incrementally reassuring", the environment remains dynamic. Last week, BTIG had said that with the bankruptcy of Tricolor and CarMax adding more reserves to its loan portfolio, general macro concerns have brought renewed interest in Carvana's financing exposure.Retail sentiment on Carvana dipped to ‘bearish’ from ‘neutral’ territory compared to a day ago, with message volumes at ‘normal’ levels, according to Stocktwits data.Auto supplier First Brands Group, which went bankrupt in late September, has seen its creditors open probes amid concerns over potential financial irregularities.BTIG had further noted last week that it does not believe Carvana will lose access to the securitization markets regardless of whether past securitizations experience impairment to their equity tranche. While the firm is closely following credit across consumers, it continues to see the company's fundamental value drivers as intact,&nbsp;it said.<a href="https://stocktwits.com/symbol/CVNA">Shares of Carvana</a> have gained 60% this year and have jumped over 71% in the last 12 months.Get updates to this developing story directly on Stocktwits.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/jefferies-ceo-claims-bank-was-defrauded-by-bankrupt-auto-supplier-first-brands-group/ch6sKBzR38y">Jefferies CEO Claims Bank Was ‘Defrauded’ By Bankrupt Auto Supplier First Brands Group</a>

In this photo illustration, a person holds a smartphone displaying the logo of Carvana. (Photo illustration by Cheng Xin/Getty Images)

Carvana Stock In Spotlight After 6% Slide Today: BTIG Maintains ‘Buy’ Rating

BTIG said that the company's September Asset-Backed Securities performance data for its closely-watched 2025-N1 issuance has shown signs of improvement.

Jefferies Financial Group (JEF) CEO Rich Handler said that the bank was “defrauded” by the auto supplier First Brands Group, which went bankrupt in late September after its creditors opened probes amid concerns over potential financial irregularities.<a href="https://stocktwits.com/symbol/JEF">Shares of Jefferies</a> were up nearly 4% in afternoon trading. The stock had closed down 11% on Thursday.“So, I'll just say this is us personally, we believe we were defrauded, okay, from a company. I personally talk to a lot of investors, a lot of CEOs, a lot of operating businesses. I think the environment is generally pretty darn good. I don't see this as the canary in the coal mine,” Handler said, according to a filing by Jefferies on Friday.“I'm not saying there aren't other issues like this. There was one yesterday that one of our competitors had to deal with. I think these things happen,” he added.Western Alliance (WAL) disclosed on Thursday that a borrower failed to provide first-position collateral loans, triggering fraud concerns and adding volatility to the markets, with shares of U.S. regional banks slumping.Earlier in the week, Jefferies said that its estimated financial losses from the bankruptcy of First Brands were relatively low. Jefferies’ investments in the troubled auto parts firms effectively comprise $43 million, or 5.9%, of Point Bonita’s accounts receivable purchased from First Brands and a small interest in First Brands’ bank loans through Jefferies Finance’s Apex platform.On October 8, Jefferies said that its Leucadia Asset Management fund, through its credit fund Point Bonita, has about $715 million invested in receivables tied to First Bank.Retail sentiment on Jefferies improved to ‘neutral’ from ‘bearish’ territory compared to a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.The disclosure from Western Alliance followed Zions Bancorp’s (ZION) announcement on Wednesday about a $50 million charge-off related to commercial and industrial loans.Despite this, Handler noted that it did not feel like the sector was on the edge of a default cycle. “I've been on the edge of default cycles before. I think that's one of the reasons why our business is doing so well right now. Private equity is flush with capital and they have to basically sell companies. Corporates feel pretty strong, so they're actually being acquisitive. And there's a functioning liquid debt and equity market right now,” he said.“And certain parts of the world are better than other parts of the world. But it doesn't feel like, you know, 2007 when the world's about to come to an end. Look at the financial sector. The financial sector across the board is usually the canary in the coal mine … So, I don't see it as the beginning of the end,” Handler added.Shares of Jefferies have declined nearly 35% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nukkleus-stock-slides-15-today/ch6sLyWR38M">Nukkleus Stock Slides 15% Today: What’s Sparking The Drop?</a>

 In this photo illustration, the Jefferies Group logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Jefferies CEO Claims Bank Was ‘Defrauded’ By Bankrupt Auto Supplier First Brands Group

Shares of regional banks fell on Thursday after Western Alliance (WAL) disclosed that a borrower failed to provide first-position collateral loans, triggering fraud concerns.

Amazon.com (AMZN) founder Jeff Bezos reportedly said that people should be thrilled about artificial intelligence (AI) and not discouraged about it.“I don’t see how anybody can be discouraged who is alive,” said Bezos, during a panel discussion at Italian Tech Week 2025 in October, according to a CNBC report.&nbsp;”[AI will make every business’] quality go up and their productivity go up ... Every manufacturing company, every hotel, every consumer products company ... That’s hard to fathom, but it’s real,” he said.According to the report, Bezos noted that different industries will all use AI at different rates, although he said he could not outline a timeline for this. He also said that AI is in an “industrial bubble,” presently with stocks trading at record highs and investors struggling to figure out “the good ideas and the bad ideas.”According to the CNBC report, Bezos said the “winners” from AI, who will use it to advance research and development irrespective of the industry, will provide “gigantic” benefits to society. “There’s never been a better time to be excited about the future,” he said.Retail sentiment on <a href="https://stocktwits.com/symbol/AMZN">Amazon</a> remained unchanged in the ‘bearish’ territory compared to a day ago, with message volumes at ‘high’ levels, according to data from Stocktwits. Shares of Amazon have gained nearly 13% in the last 12 months.The report added that not many people agree with what Bezos expressed, according to Pew Research Center data, which was published on Wednesday. In a global survey, a median of 34% of adults told Pew they’re more concerned than excited about “the rise of AI in daily life.”According to Pew, 42% said they’re equally concerned and excited, and 16% said they’re more excited than concerned, the report stated. It noted that worries over AI are stronger in the U.S., where 50% of respondents told Pew they were more concerned than excited, and 38% said they were equally concerned and excited.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/oklo-stock-in-spotlight-after-announcing-2-b-nuclear-pact/ch6s9INR38K">Oklo Stock In Spotlight After Announcing $2B Pact For Advancing US Nuclear Fuel Ecosystem</a>

Jeff Bezos at The 11th Breakthrough Prize Ceremony held at Barker Hanger on April 05, 2025 in Santa Monica, California. (Photo by Gilbert Flores/Variety via Getty Images)

Jeff Bezos Reportedly Says People Should Be Thrilled About AI: ‘Don’t See How Anybody Can Be Discouraged Who Is Alive’

According to a CNBC report, Bezos noted that different industries will all use AI at different rates, although he said he could not outline a timeline for this.

Eli Lilly and Company (LLY) on Friday stated that two years of adjuvant Verzenio plus endocrine therapy reduced the risk of death by 15.8% as compared to endocrine therapy alone in a late-stage trial in patients with a certain type of high-risk early breast cancer.According to the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.lilly.com/news-releases/news-release-details/lillys-verzenior-abemaciclib-prolonged-survival-hr-her2-high">firm</a>, Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in this type of breast cancer.Furthermore, treatment with Verzenio plus endocrine therapy led to a sustained reduction in risk of recurrence at seven years, Lilly said. The company noted that 32% fewer patients treated with Verzenio plus ET were living with metastatic disease compared to those receiving ET alone after seven years.“Continued long-term follow-up from this trial will help to determine whether this ongoing difference in patients alive with metastatic disease translates into further deepening of survival benefit with time,” the company said.The data is being submitted to health authorities worldwide, the company said. Jacob Van Naarden, executive vice president and president of Lilly Oncology, termed the study results an “important advancement” in the care of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer.Safety findings were consistent with the known profile of Verzenio, and adverse events were generally managed with dose modifications in the study, the company added.<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> traded 4% lower in the pre-market session at the time of writing after President Trump <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-novo-nordisk-stocks-fall-after-hours-trump-pledges-swift-price-cuts-for-fat-loss-drugs/ch6rwjbR3Fa">said</a> on Thursday that the price of its rival Novo Nordisk’s weight-loss drug would be lowered. On Stocktwits, retail sentiment around LLY stock stayed within the ‘bearish’ territory while message volume rose from ‘low’ to ‘high’ levels.LLY stock is up by 6% this year but has fallen 11% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/protalix-biotherapeutics-stock-tumbles-after-negative-chmp-opinion/ch6s74tR389">Protalix BioTherapeutics Stock Tumbled 28% Today: Why The Latest CHMP Opinion Is Sparking Concerns Among Investors?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. (Photo by Scott Olson/Getty Images)

Eli Lilly Says Verzenio Reduced Risk of Death In Late-Stage Trial In Some Breast Cancer Patients

According to Lilly, Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in this type of breast cancer.

Boston Scientific Corporation (BSX) said on Friday that it has entered into a definitive agreement to acquire privately held medical technology company Nalu Medical for an upfront cash payment of approximately $533 million for equity not currently owned by the company.Nalu is developing minimally invasive solutions for patients with chronic pain, and Boston Scientific has been a strategic investor in the company since 2017.The transaction is <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/boston-scientific-announces-agreement-to-acquire-nalu-medical-inc-302587495.html">expected</a> to be completed in the first half of 2026, subject to the satisfaction of customary closing conditions. The transaction is not expected to impact Boston Scientific’s adjusted earnings per share (EPS) in 2026. However, the company expects it to be slightly accretive to adjusted EPS in 2027 and increasingly accretive thereafter.BSX shares traded down 1% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BSX">BSX stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.The acquisition is intended to expand the neuromodulation offerings for people living with chronic pain, Boston Scientific said."Adding the highly differentiated Nalu Medical technology complements our existing therapies—including spinal cord stimulation, basivertebral nerve ablation and radiofrequency ablation—enabling us to deliver advanced pain relief options to a wider variety of patient populations," President Jim Cassidy said.Nalu is expected to generate sales of more than $60 million in 2025 and to deliver year-over-year growth of over 25% in 2026.BSX stock is up by 9% this year and by about 13% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-falls-below-105-000-pulling-mstr-stock-lower-xrp-and-solana-drop/ch6sexmR383">Bitcoin Falls Below $105,000, Pulling MSTR Lower – XRP And Solana Drop Amid Banking Jitters</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A general view of a Boston Scientific advertisement during a women's college lacrosse game between the Notre Dame Fighting Irish and the Boston College Eagles on March 16, 2024. (Photo by Erica Denhoff/Icon Sportswire via Getty Images)

Boston Scientific To Acquire Privately-Held Pain Solutions Developer Nalu Medical For About $533M

Nalu Medical is developing minimally invasive solutions for patients with chronic pain, and Boston Scientific has been a strategic investor in the company since 2017.

Vanguard Group, Inc. - Vanguard U.S. Momentum Factor ETF

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

VFMO
Vanguard Group, Inc. - Vanguard U.S. Momentum Factor ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VFMO News

VFMOVanguard Group, Inc. - Vanguard U.S. Momentum Factor ETF